

THE FODMAP DIET AND PROMITOR® SOLUBLE FIBRE

Popularity of FODMAP (fermentable oligo-, di-, and monosaccharide and polyol) diets has been increasing, especially for consumers concerned with Irritable Bowel Syndrome (IBS) or digestive health¹. This dietary plan was developed by a team of scientists at Monash University, Australia, who proposed that FODMAPs could cause the symptoms of IBS, and therefore reducing FODMAPs can be beneficial to these patients⁴. One of the shortcomings of the FODMAP diet is that it can often be low in fibre². Therefore, fibre ingredients that are well tolerated and free of FODMAP components would have significant impact. Yet, high levels of some dietary fibres are sometimes associated with gastrointestinal (GI) side effects such as bloating, intestinal noises, cramping, flatus and diarrhoea. These effects are due primarily to the production of gases by fermentation of fibre in the large intestine. In general, smaller molecules (e.g. FOS³, sorbitol) are more rapidly fermented, and thus more likely to cause side effects. Larger molecules that ferment more slowly (e.g. PROMITOR® Soluble Fibre) are usually better tolerated.

Fermentable
Oligosaccharides
Disaccharides
Monosaccharides
And
Polyols

FODMAP dietary plan: Examples of each of these FODMAP groups can be seen in Table 1.

Table 1. Examples of FODMAP restricted dietary components⁵

FODMAP restricted dietary component	Definition	Dietary Examples	Common Food Sources
Oligosaccharides	3 to 10 saccharide units	Inulin FOS GOS	Wheat Onion Garlic Legumes/pulses
Disaccharides	2 saccharide units	Lactose	Milk Soft cheeses Yogurt
Monosaccharides	single saccharide unit	Fructose	Honey Apples HFCS
Polyols	sugar alcohols	Sorbitol Mannitol	Some fruits Some vegetables Artificial sweeteners

The FODMAP dietary plan is two phased. First, the diet consists of a strict reduction of all FODMAP components. This is followed by the second phase where there is reintroduction of specific FODMAPs according to an individual's gastrointestinal tolerance over a period of 2-6 weeks^{2,4}

PROMITOR® SOLUBLE FIBRE CONTAINS NO FOS, GOS, FRUCTOSE, LACTOSE OR POLYOLS.

PROMITOR® Soluble Fibre has excellent tolerance. A number of human clinical trials have been conducted to assess gastrointestinal tolerance to PROMITOR® Soluble Fibre and have shown that multiple doses can be consumed several times a day up to 65 grams without significant clinical gastrointestinal symptoms⁶⁻¹². A single dose up to 40 g PROMITOR® Soluble Fibre a day is well tolerated and most individuals will not have noticeable GI side effects⁸. The food matrix and the timing throughout the day of the dose does not seem to impact tolerance. PROMITOR® Soluble Fibre has better overall tolerance than inulin or FOS. In general, smaller molecules (e.g. fructooligosaccharide (FOS), sorbitol) are more osmotic (have the ability to pull water into the intestines) and rapidly fermented, and thus more likely to cause GI side effects. Larger molecules that ferment more slowly and are less osmotic, are usually better tolerated.

Conclusion:* PROMITOR® Soluble Fibre can help bridge the fibre intake gap and allow product developers to create FODMAP friendly products because PROMITOR® contains no FODMAP components. Specifically, PROMITOR® Soluble Fibre contains no FOS, GOS, fructose, lactose or polyols.

Contact the Global Nutrition team to learn more about the FODMAP diet and reach out to your sales representative or technical application scientist to learn more about how Tate & Lyle ingredients can be utilized to reduce carbohydrates or calories in your product formulation.

1. Mintel. Consumer Approach to Nutrition - US - January 2020.
2. Hill P, Muir JG, Gibson PR. Controversies and Recent Developments of the Low-FODMAP Diet. *Gastroenterol Hepatol (N Y)*. Jan 2017;13(1):36-45.
3. Hustoft TN, Hausken T, Ystad SO, et al. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. *Neurogastroenterol Motil*. Apr 2017;29(4).
4. FODMAP Program. <https://www.monashfodmap.com/>. Accessed 02/05/2020.
5. Low FODMAP Diet. <http://shepherdworks.com.au/disease-information/low-fodmap-diet/>. Accessed 02/05/2020.
6. Stewart ML, Nikhanj SD, Timm DA, Thomas W, Slavin JL. Evaluation of the effect of four fibers on laxation, gastrointestinal tolerance and serum markers in healthy humans. *Ann Nutr Metab*. 2010;56(2):91-98.
7. Whisner CM, Martin BR, Nakatsu CH, et al. Soluble maize fibre affects short-term calcium absorption in adolescent boys and girls: a randomised controlled trial using dual stable isotopic tracers. *Br J Nutr*. Aug 14 2014;112(3):446-456.
8. Housez B, Cazaubiel M, Vergara C, et al. Evaluation of digestive tolerance of a soluble corn fibre. *J Hum Nutr Diet*. Oct 2012;25(5):488-496.
9. Boler BM, Seroo MC, Bauer LL, et al. Digestive physiological outcomes related to polydextrose and soluble maize fibre consumption by healthy adult men. *Br J Nutr*. Dec 2011;106(12):1864-1871.
10. Karalus M, Clark M, Greaves KA, et al. Fermentable fibers do not affect satiety or food intake by women who do not practice restrained eating. *J Acad Nutr Diet*. Sep 2012;112(9):1356-1362.
11. Timm DA, Thomas W, Boileau TW, Williamson-Hughes PS, Slavin JL. Polydextrose and soluble corn fiber increase five-day fecal wet weight in healthy men and women. *J Nutr*. Apr 2013;143(4):473-478.
12. Klosterbuer AS, Hullar MA, Li F, et al. Gastrointestinal effects of resistant starch, soluble maize fibre and pullulan in healthy adults. *Br J Nutr*. Sep 28 2013;110(6):1068-1074.

* These statements should be re-evaluated as novel scientific literature is published.

Disclaimer: The contents of this document are strictly for general informational and education purposes. This is not intended to be an endorsement or in any way a promotion of the FODMAP diet, nor is it intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.